| Stereochemistry | ACHIRAL |
| Molecular Formula | C24H28N4O4 |
| Molecular Weight | 436.5035 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=CC(=C1)C(=O)NC2=CC(C3=CC=NN3C)=C(OCCN4CCOCC4)C=C2
InChI
InChIKey=ZEOQUKRCASTCFR-UHFFFAOYSA-N
InChI=1S/C24H28N4O4/c1-27-22(8-9-25-27)21-17-19(26-24(29)18-4-3-5-20(16-18)30-2)6-7-23(21)32-15-12-28-10-13-31-14-11-28/h3-9,16-17H,10-15H2,1-2H3,(H,26,29)
| Molecular Formula | C24H28N4O4 |
| Molecular Weight | 436.5035 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Temanogrel (also known as APD791) is an oral small molecule inverse agonist of the serotonin 2A (5-HT2A) receptor with potent activity on platelets and vascular smooth muscle. Temanogrel has been studied in phase I clinical trials in healthy subjects to assess its pharmacokinetics, pharmacodynamics, and safety. However, these studies were terminated because of the sponsor’s decision.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
PubMed
Patents
|
|
SALT/SOLVATE -> PARENT | |||
|
|
TARGET->INVERSE AGONIST |
|
Showing 1 to 2 of 2 entries
